🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07734610
Recruiting Phase 1

A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)

NCT07734610 · tracked via the Priya Life Science USA tracker
Sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1
Started
2026-09-17
Last updated
2026-09-17

Condition(s) studied

Severe Renal ImpairmentHealthy

Investigational drug(s) / intervention(s)

Nemtabrutinib

Nemtabrutinib: Oral administration

Study summary

The purpose of this study is to learn what happens to nemtabrutinib in a person's body when given to participants with severe kidney disease and to healthy participants.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: All participants: * Has a body mass index (BMI) ≥18.0 and ≤40.0 kg/m\^2 Participants with Severe Renal impairment (RI): * The participant has stable renal function as determined by historical measurements. Healthy volunteers: * Is medically healthy with no clinically significant medical history Exclusion Criteria: The main exclusion criteria include but are not limited to the following: Renal Impairment Participants: * History of any illness, other than renal impairment, that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study. Healthy Matched Control Participants: * History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases. Participants with a remote history of uncomplicated medical events (eg, uncomplicated kidney stones, as defined as spontaneous passage and no recurrence in the last 5 years, or childhood asthma) may be enrolled in the study at the discretion of the investigator

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Floridian Clinical Research, LLC ( Site 0001) Miami Lakes Florida Recruiting

More Merck Sharp & Dohme LLC trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07734610 on ClinicalTrials.gov ↗ ← All trials in the USA